Dr. Jason Marshall has been engaged in the discovery, development, characterization, and optimization of vaccine candidates for a variety of infectious disease and cancer indications for clinical development for 24 years. At Dynavax, he was engaged in discovering and characterizing the activity of new classes of CpG-based adjuvants and optimizing their performance in various vaccines. At MedImmune, he progressed vaccine candidates for HBV, EBV, HSV, RSV, and Staphylococcus through preclinical development in animal models, including mouse, rat, ferret, and guinea pig. These projects included working with diverse adjuvant formulations, including emulsions, liposomes, nanoparticles, TLR agonists, and viral vectors.
At the Cancer Immunoprevention Laboratory at Frederick National Laboratory, he has focused on advancing successful immunoprevention concepts in preclinical development toward investigational new drug and clinical development since 2016. CIPL efforts support several PREVENT programs, including vaccine strategies targeting HPV-induced cervical and oral pharyngeal cancers, Lynch Syndrome colorectal cancer, prostate, ovarian, and other solid tumor cancers using syngraft and genetically engineered mouse models. We have developed vaccines using formats such as peptides, VLPs, vesicles, nanoparticles, and RNAs.
